PEPTIDEPEDIA
Rejoindre
AOD-9604 vs HGH Fragment 176-191: Identity and Evidence illustration
Mélange commercialisé
B 0012026-08-06

AOD-9604 vs HGH Fragment 176-191: Identity and Evidence

Tous les mélangesAOD-9604 (Tyr-hGH 177-191)HGH Fragment 176-191
Représentation de structure idéalisée pour AOD-9604 vs HGH Fragment 176-191: Identity and Evidence
B 001AOD-9604 (Tyr-hGH 177-191) · HGH Fragment 176-191

Conformère idéalisé construit à partir de la séquence ; il ne s’agit ni d’une structure expérimentale ni d’une structure prédite.

Le contenu des preuves est maintenu en anglais.

Bottom line

A boundary-case entry: AOD-9604 and HGH Fragment 176-191 are not a "blend" of distinct peptides but two variant forms of the same C-terminal fragment of human growth hormone, often confused or marketed interchangeably. AOD-9604 (Tyr-hGH 177-191) is a pharmaceutical optimisation with published Phase II human data; HGH Fragment 176-191 is the unmodified native sequence with no independent human trial data.

No established or recommended human dose.

Name and formulation variability

Observed market contextExact material claimedIdentity relevanceVerification limits
Paired market claims“AOD-9604 + HGH Frag 176-191”Related identities presented together, not a standardized blendSeller declaration only
AOD-9604-alone claims“AOD-9604”Should refer to Tyr-hGH 177-191 identity and reports vary
Native-fragment claims“HGH Frag 176-191”Often conflated with AOD-9604Exact identity not independently verified

These are often marketed as a "stack" for fat loss but are chemically distinct variants of the same GH region, not complementary peptides.

Sequence boundary
AOD-9604 and native HGH fragment 176-191 are related but distinct identitiesTwo abstract sixteen-position residue rails highlight the page-described N-terminal difference. Evidence cards remain attached to the exact material, and a blocked double arrow prevents transfer.NATIVE HGH FRAGMENT 176-191AOD-9604 / TYR-hGH 177-191176•••••••••••••••TYR•••••••••••••••MODIFIED IDENTITYnative fragmentseparate evidence cardAOD-9604human evidence cardNAMES OFTEN CONFLATED; EVIDENCE NOT TRANSFERABLEIDENTITYHYPOTHESIZED / SHARED DOMAINMARKET ASSOCIATIONEVIDENCE GAP
The rails are abstract identity positions, not structural depictions. Legend: solid outlines identify the substances described on the page; dashed lines show hypothesized or shared biological domains; dotted lines show market association only; barred lines mark missing combination or compatibility evidence.
Alternative textuelle

Native HGH fragment 176-191 and AOD-9604, described here as Tyr-hGH 177-191, each span sixteen abstract positions but differ at the N terminus. The modified identity boundary prevents AOD-9604 human findings from being assigned to the native fragment. Market names are often conflated, but evidence is not transferable.

Market-claim detail

Observed listings included variable declarations and claims in the 2–5 mg range for either name. These seller declarations add no identity or clinical evidence and are not guidance.

Component evidence

Exact materialHuman evidenceCombination claimCompatibility relevance
AOD-9604 (Tyr-hGH 177-191)Six phase 1/2 studies were reported; the 24-week phase 2b study enrolled 536 participants and failed its primary endpoint. Development was discontinued in 2007.No meaningful standardized combination identifiedThe identities are related variants, not compatibility evidence
Native HGH Fragment 176-191No published human trial identified; AOD-9604 data are often reassigned incorrectlyNo meaningful standardized combination identifiedAOD-9604 evidence cannot establish the native fragment's properties

AOD-9604 is distinguished by an N-terminal tyrosine that improves stability. The grey-market HGH Frag 176-191 lacks this modification.

Combination-specific studies

No study has tested AOD-9604 + HGH Frag 176-191 as a combination because they are variant forms of the same peptide, not complementary agents.

Safety and interaction uncertainties

  • AOD-9604 well-tolerated in Phase I/II; no IGF-1 elevation; no glucose disruption

  • Unmodified HGH Frag 176-191 has no human safety data

  • GRAS notice (GRN 000792) for food ingredient use — not a drug approval

  • : both prohibited as GH fragments ( class)

Regulatory and product-quality notes

  • Neither is FDA-approved for any indication

  • AOD-9604 was an drug; development terminated 2007

  • Mislabeling between AOD-9604 and HGH Frag 176-191 is widespread

  • FDA enforcement actions against compounders marketing unapproved peptides

Evidence gaps

  • No human trial data for HGH Frag 176-191 specifically

  • AOD-9604's published trial data never appeared in PubMed-indexed journals

  • No established or recommended human dose for either exact material

  • Widespread vendor confusion between the two variants

The market-claim detail is kept in a subordinate disclosure because seller amounts add no identity evidence. See identity methodology, WADA and sport, and the blend index.

Sources

  1. Clinical Peptide. AOD-9604 vs HGH Fragment 176-191. https://clinicalpeptide.org/compare/aod-9604-vs-hgh-frag-176-191/ accessed 2026-08-06.

  2. PeptideBase. AOD-9604 Research Guide. https://peptidebase.io/peptides/aod-9604 accessed 2026-08-06.

  3. HealthRX. HGH Frag 176-191 Evidence. https://healthrx.com/peptides-specialty/hgh-frag-176-191 accessed 2026-08-06.

  4. Useful Vitamins. AOD-9604 Explained. https://usefulvitamins.com/aod-9604-explained/ accessed 2026-08-06.

  5. Heffernan M, et al. Endocrinology. 2001;142(11):4723-4730. PMID 11713213.

Voix d'experts

Ce que disent les experts

Les commentaires sont des opinions et ne font pas partie de l'examen des preuves ; leur inclusion ne vaut pas approbation.

Aucun commentaire d’expert vérifié n’a été trouvé pour ce composé dans les sources acceptées par cet atlas — littérature évaluée par les pairs, communications universitaires, hospitalières et de sociétés médicales, autorités réglementaires, et journalisme scientifique signé.

L’absence de commentaire ne constitue pas une preuve pour ou contre le composé.

Les affirmations émanant de fournisseurs, cliniques et médias sociaux sont exclues par politique et ne sont pas comptées comme commentaires.

Aucune vidéo d’expert vérifiée n’a été trouvée pour ce composé dans les sources de cet atlas.

L’absence de vidéo ne constitue pas une preuve pour ou contre le composé.

Les vidéos de fournisseurs et de médias sociaux sont exclues par politique et ne sont pas comptées.

Questions

What is the AOD-9604 and HGH Fragment 176-191 boundary case?

It compares two related but distinct identities from the same growth-hormone region rather than a standardized blend of complementary peptides. Market sources often conflate their names.

Has AOD-9604 plus native HGH Fragment 176-191 been studied as a combination?

No combination study was identified. The page treats the pairing as an identity-confusion case, while human findings remain attached to AOD-9604 alone.

What safety and regulatory uncertainties apply to the AOD-9604 boundary case?

The native fragment lacks identified human safety evidence, neither exact material is FDA-approved, and AOD-9604 development was discontinued. A food-ingredient GRAS notice is not a medicine approval.

Are AOD-9604 and native HGH fragment 176-191 identical?

No. The page defines AOD-9604 as Tyr-hGH 177-191 and distinguishes its modified N terminus from native HGH fragment 176-191.

Can AOD-9604 trial results be assigned to the native fragment?

No. Trial evidence follows the exact studied material, and the native fragment has a different identity with no independent published human trial identified.

Why is this page in the blend atlas?

Market sources pair or conflate the related names even though no meaningful standardized combination is established. The page documents that naming boundary without treating it as combination evidence.